Stephen P. Errico, PE

Stephen Errico is the ASO Portfolio Management Lead at Biogen and is responsible for the planning of antisense oligonucleotide process development and clinical and commercial manufacturing activities. His planning activities insure that new ASO medicines can be delivered as fast as possible to address the unmet needs of patients. He has been at Biogen for three years. Stephen has over thirty years of experience in the bio-pharmaceutical industry and has worked in several different capacities. He has held leadership positions in engineering and maintenance, capital programs and sterile drug product manufacturing for Wyeth and Eisai. Steve holds a bachelor’s degree engineering chemistry from the University at Stony Brook, bachelor’s and master’s degrees in chemical engineering from Manhattan College and an MBA from NC State University.